One dose of a monoclonal antibody (mAb) safely protected healthy, nonpregnant adults from malaria infection during an intense six-month season of malaria in Mali, Africa, according to a presentation at the American Society of Tropical Medicine and Hygiene 2022 Annual Meeting, in Seattle.
The phase 2 trial evaluated the safety and efficacy of a one-time IV infusion of CIS43LS, which was previously shown to neutralize the sporozoites of Plasmodium falciparum in the skin and